Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Gene Profile in EGFRm Locally Advanced or Metastatic NSCLC Patients Post Osimertinib 1L Treatment Failure: A Real-world, Multi-center Study (GPS)

NCT05219162 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05219162
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05219162 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Gene Profile in EGFRm Locally Advanced or Metastatic NSCLC Patients Post Osimertinib 1L Treatment Failure: A Real-world, Multi-center Study (GPS)
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Completed
Start date
February 25, 2022
Completion date
April 29, 2024
Enrollment
182 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

advanced nsclc